Hinge Health Q3 2026 earnings

HNGE · 2026-11-02 16:06 AMC ET · 8-K on SEC

Record Q3 revenue and free cash flow with raised full-year guidance and margin expansion.

Headline numbers

MetricActualYoYQoQ8-K location
Revenue$235.0M+52%+10.5%Ex. 99.1, Financial Highlights
EPS (GAAP)$0.66+N/A+0.14Ex. 99.1, Financial Highlights
EPS (adjusted)$0.71+121%+0.12Ex. 99.1, Financial Highlights
Net income$57.4M+N/A+13.7MEx. 99.1, Financial Highlights
Adj. EBITDA$77.2M+154%+15.7MEx. 99.1, Financial Highlights
Adj. EBITDA margin33%+13 pp+4 ppEx. 99.1, Financial Highlights

Revenue breakdown

not stated in the 8-K

Margins and costs

  • Gross margin 87% (prior 82%, change +5 pp)
  • Operating expenses $154.0M (+16.6% YoY)
  • One-offs in the quarter Acquisition-related expenses: $80k; Acquisition-related expenses: $2.6M (Non-GAAP)
  • Effective tax rate N/A
  • Non-GAAP bridge Adds back stock-based compensation, employer payroll tax, amortization, and acquisition-related expenses.

KPIs

MetricActualPrior quarterPrior yearChange
Free cash flow$112.7M$99.6M$81.3M+13.1M QoQ, +38.4% YoY
LTM billings$960.3M$861.8M$624.2M+98.5M QoQ, +54% YoY
Number of clients3,2702,9292,560+341 QoQ, +28% YoY

Guidance

MetricGuidePrior guideChange
Q4 2026 Revenue$249M-$251M$223M-$225M+26M-$28M
Q4 2026 Non-GAAP Operating Margin33% (midpoint)28% (midpoint)+5 pp
FY 2026 Revenue$879M-$881M$856M-$860M+23M-$25M
FY 2026 Non-GAAP Operating Margin30% (midpoint)28% (midpoint)+2 pp

What drove it

  • Revenue story Revenue increased 52% YoY to $235.0M, driven by continued high member conversion and a record sales season.
  • EPS story Non-GAAP EPS increased 121% YoY to $0.71, driven by revenue growth and margin expansion.
  • One-off check Acquisition-related expenses of $80k (GAAP) and $2.6M (Non-GAAP) for Cylinder Health.

The good

  • Revenue grew 52% YoY to $235.0M
  • Free cash flow increased to $112.7M
  • Non-GAAP operating margin expanded to 33%

The bad

  • none

The ugly

  • none

Open questions

  • Details on the integration and synergies of the Cylinder Health acquisition
  • Specifics on the launch timeline for the integrated Gastrointestinal Care Program
Full release

Hinge Health (HNGE) earnings release, November 2, 2026

Hinge Health, Inc. (HNGE) · Form 8-K, Item 2.02 · Filed · SEC filing

Hinge Health reports record third quarter 2026 financial results

• Revenue increased 52% year-over-year to $235 million

• Free cash flow of $113 million, representing a 48% free cash flow margin

• 2026 revenue guidance midpoint raised to $880 million, reflecting 50% year-over-year growth

• 2026 non-GAAP operating margin midpoint raised to 30%, reflecting ~1,000 bps improvement year-over-year

San Francisco, California – November 2, 2026 – Hinge Health, Inc. (NYSE: HNGE) today announced financial results for the third quarter ended September 30, 2026 and provided a business update.

“Our strong performance continues to reflect our ability to deliver exceptional clinical outcomes, a better healthcare experience and lower client costs at scale," said Daniel Perez, Co-Founder and CEO, Hinge Health. "This focus on the triple aim, via a technology platform that scales and automates care delivery, is also resulting in a record sales season. Our client base is up almost 30% YoY for our MSK Care Program, roughly 40% for our GI Care Program since our acquisition announcement of Cylinder Health in August, and has nearly doubled for our Migraine Care Program since last quarter."

Third Quarter Financial Highlights:

• Revenue increased 52% year-over-year to $235.0 million compared to revenue of $154.2 million in Q3 2025.

• GAAP gross margin was 87% compared to 82% in Q3 2025.

Non-GAAP gross margin was 88% compared to 83% in Q3 2025.

• GAAP income from operations increased to $50.3 million compared to GAAP loss from operations of $6.1 million in Q3 2025.

Non-GAAP income from operations increased 154% to $77.2 million compared to $30.4 million in Q3 2025.

• GAAP operating margin was 21% compared to (4)% in Q3 2025.

Non-GAAP operating margin was 33% compared to 20% in Q3 2025.

• GAAP diluted net income per share was $0.66 compared to a GAAP diluted net loss per share of $0.

02 in Q3

2025.

Non-GAAP diluted net income per share was

$0.71 compared to $0.32 in Q3 2025.

• Net cash provided by operating activities increased to $114.6 million compared to $82.4 million in Q3 2025.

Free cash flow increased to $112.7 million compared to $81.3 million in Q3 2025.

• Cash, cash equivalents, marketable securities and restricted cash were $358.5 million as of September 30, 2026.

Company Highlights and Key Metrics:

• LTM calculated billings increased 54% year-over-year to $960.3 million as of September 30, 2026, compared to $624.2 million as of September 30, 2025.

• Number of clients increased 28% year-over-year to 3,270 clients as of September 30, 2026, compared to 2,560 clients as of September 30, 2025.

Leadership Update

We also announced that Jim Pursley will step down as President, effective January 1, 2027, and will join our Board of Directors, effective January 4, 2027. Following this transition, Aaryn Pure will lead the commercial organization as Chief Commercial Officer.¹

“We wouldn't be the company we are today if not for Jim,” said Daniel Perez, Co-Founder and CEO, Hinge Health. “He's been instrumental in our scaling to over 3,200 clients. I'm grateful for all he's done and that he'll continue contributing to our success as a board member and advisor.”

Financial Outlook:

We are providing the following guidance for our fourth quarter 2026 and full year 2026:

• Q4 2026:

We expect revenue to be between $249 million and $251 million, reflecting year-over-year growth of 46% at the midpoint. We expect non-GAAP income from operations to be between $81 million and $83 million, reflecting year-over-year growth of 71% and non-GAAP operating margin of 33% at the midpoint, a ~470 bps increase over Q4 2025.

• Full Year 2026:

We are raising our revenue guidance to be between $879 million and $881 million, reflecting year-over-year growth of 50% at the midpoint. We are raising our non-GAAP income from operations guidance to be between $266 million and $268 million, reflecting year-over-year growth of 123% and non-GAAP operating margin of 30% at the midpoint, a ~1,000 bps increase over 2025.

Statement Regarding Use of Non-GAAP Financial Measures

This press release uses non-GAAP financial measures, which are not calculated in accordance with generally accepted accounting principles of the United States (GAAP). For more information about these non-GAAP financial measures, including the limitations of such measures, and for a reconciliation of each measure to the most directly comparable measure calculated in accordance with GAAP, please see the “Non-GAAP Financial Measures” section below.

Moreover, we have not reconciled our non-GAAP income from operations and non-GAAP operating margin guidance to GAAP income from operations and GAAP operating margin because we do not and are not able to provide guidance for GAAP income from operations due to the uncertainty and potential variability of stock-based compensation expense, employer payroll tax expense related to stock-based compensation, amortization of intangible assets and adjustments, such as acquisition-related expense, which are reconciling items between non-GAAP and GAAP income from operations and operating margin. Because such items cannot be provided without unreasonable efforts, we are unable to provide a reconciliation of the non-GAAP financial measure guidance to the corresponding GAAP measures. However, such items could have a significant impact on our future GAAP income from operations.

Hinge Health Earnings Webcast

We will host a conference call and webcast for investors on November 2, 2026 at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) to discuss our financial results, business highlights and financial outlook. The live webcast of the conference call can be accessed by registering online at ir.hingehealth.com/events-presentations. Following completion of the event, a webcast replay will also be available at ir.hingehealth.com for 12 months.

About Hinge Health... (truncated)ealth care. Leveraging an AI-powered care model, connected hardware and access to expert clinicians, Hinge Health delivers personalized, evidence-based care that improves member outcomes and experiences while reducing costs for clients. The company is headquartered in San Francisco, California.

Available Information

Our investors and others should note that we announce material information to the public about our company, products and services, and other matters related to our company through a variety of means, including filings with the U.S. Securities and Exchange Commission (“SEC”), the investor relations page on our website (ir.hingehealth.com), press releases, public conference calls, and webcasts in order to achieve broad, non-exclusionary distribution of information to the public and to comply with our obligations under Regulation FD.²

Financial statements

Income Statement

Three Months Ended September 30, — (in thousands, except per share data)

Three Months Ended September 30, – 2026Three Months Ended September 30, – 2025Nine Months Ended September 30, – 2026Nine Months Ended September 30, – 2025
Revenue234,970154,211630,094417,134
Cost of revenue30,64028,01287,58292,939
Gross profit204,330126,199542,512324,195
Operating expenses:
Research and development37,47331,921101,868335,382
Sales and marketing85,24163,520235,451257,464
General and administrative31,29136,85182,359304,976
Total operating expenses154,005132,292419,678897,822
Income (loss) from operations50,325-6,093122,834-573,627
Other income:
Other income, net3,3924,45511,25514,147
Net income (loss) before income taxes53,717-1,638134,089-559,480
(Benefit from) provision for income taxes-3,681206-2,128876
Net income (loss)57,398-1,844136,217-560,356
Adjustment to reflect deemed contribution from Series D and Series E redeemable convertible preferred stock extinguishment104,174
Income allocated to participating securities-2,051
Net income (loss) attributable to common stockholders, basic57,398-1,844134,166-456,182
Net income (loss) attributable to common stockholders, diluted57,398-1,844134,307-456,182
Net income (loss) attributable to common stockholders per share:
Basic0.71-0.021.69-9.88
Diluted0.66-0.021.58-9.88
Weighted average shares used in computing net income (loss) per share attributable to common stockholders:
Basic80,86878,85879,49346,173
Diluted86,52678,85885,07346,173

Income Statement

Three Months Ended September 30, — Reconciliation of GAAP to Non-GAAP Financial Measures:

Three Months Ended September 30, – 2026Three Months Ended September 30, – 2025Nine Months Ended September 30, – 2026Nine Months Ended September 30, – 2025
GAAP gross profit204,330126,199542,512324,195
GAAP gross margin87828678
Non-GAAP adjustments:
Stock-based compensation expense (1)9591,4012,92417,842
Employer payroll tax expense related to stock-based compensation13440284933
Amortization of intangible assets6492241,098630
Acquisition-related expenses8080
Non-GAAP gross profit206,152127,864546,898343,600
Non-GAAP gross margin88838782

Income Statement

Three Months Ended September 30, — Reconciliation of GAAP to Non-GAAP Financial Measures:

Three Months Ended September 30, – 2026Three Months Ended September 30, – 2025Nine Months Ended September 30, – 2026Nine Months Ended September 30, – 2025
GAAP income (loss) from operations50,325-6,093122,834-573,627
GAAP operating margin21-419-138
Non-GAAP adjustments:
Stock-based compensation expense (1)19,54034,84750,324625,837
Employer payroll tax expense related to stock-based compensation3,5162286,31614,455
Amortization of intangible assets1,2112241,660630
Acquisition-related expenses2,6171,1713,7514,139
Non-GAAP income from operations77,20930,377184,88571,434
Non-GAAP operating margin33202917

Income Statement

Three Months Ended September 30, — Stock-based compensation expense:

Three Months Ended September 30, – 2026Three Months Ended September 30, – 2025Nine Months Ended September 30, – 2026Nine Months Ended September 30, – 2025
Cost of revenue9591,4012,92417,842
Research and development7,5518,25918,102257,068
Sales and marketing6,0505,96016,019101,010
General and administrative4,98019,22713,279249,917
Total stock-based compensation expense19,54034,84750,324625,837

Balance Sheet

September 30, 2026 — (in thousands, except par value data)

September 30, 2026December 31, 2025
Current assets:
Cash and cash equivalents211,553207,995
Short-term marketable securities83,102155,867
Accounts receivable, net of allowance for credit losses of $7,647 and $6,092 as of September 30, 2026 and December 31, 2025, respectively148,53266,061
Deferred commissions46,59931,344
Inventory19,18615,636
Prepaid expenses and other current assets58,89157,001
Total current assets567,863533,904
Long-term marketable securities59,542113,172
Goodwill113,03064,096
Intangible assets, net68,3282,512
Property, equipment and software, net13,98910,490
Operating lease right-of-use assets33,3176,861
Other assets18,01213,726
Total assets874,081744,761
Current liabilities:
Accounts payable and accrued liabilities80,81657,331
Operating lease liabilities4,7214,223
Deferred revenue459,174300,855
Total current liabilities544,711362,409

Cash Flow

Three Months Ended September 30, — (in thousands)

Three Months Ended September 30, – 2026Three Months Ended September 30, – 2025Nine Months Ended September 30, – 2026Nine Months Ended September 30, – 2025
Operating activities:
Net income (loss)57,398-1,844136,217-560,356
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and amortization2,2211,2644,4553,910
Stock-based compensation19,54034,84750,324625,837
Amortization of deferred commissions21,71612,56657,00632,436
Accretion of discounts and amortization of premiums on marketable securities, net551501,255376
Non-cash operating lease expense1,1528612,9862,549
Provision for credit losses9145602,5273,340
Deferred taxes-3,31350-3,300146
Other4-22
Changes in operating assets and liabilities:
Accounts receivable-18,41811,974-79,402-47,610
Deferred commissions-25,167-10,670-74,246-38,320
Inventory-2,119175-3,251-2,939
Prepaid expenses and other current assets9,405-1,393-1,915-8,002
Other assets492-7,664165-8,149
Accounts payable and accrued liabilities9,99817,99312,59024,990
Operating lease liabilities-898-932-3,052-2,724
Deferred revenue41,13024,557156,74182,062
Net cash provided by operating activities114,60282,398259,098107,548
Investing activities:
Purchase of property and equipment-376-52-582-300
Capitalized internal use software-1,568-1,065-4,746-3,401
Purchases of marketable securities-142,898-89,877-318,180
Maturities of marketable securities44,15785,258214,117249,814
Acquisition of a business, net of cash acquired-97,353-97,353-4,000
Cash paid for an asset acquisition-9,036-9,036
Net cash provided by (used in) investing activities-64,176-58,75712,523-76,067
Financing activities:
Proceeds from exercise of common stock options202531882787
Issuance of common stock in connection with the employee stock purchase plan7,276
Proceeds from issuance of common stock in initial public offering, net of issuance costs255,675
Repurchase and retirement of common stock-25,893-157,384
Tax withholdings on settlement of restricted stock units and performance-based restricted stock units-96,565-116,356-272,258
Payment on Repurchase Agreement with Coatue-50,000
Proceeds from repayment of non-recourse loans to employees4,934
Payments for deferred offering costs-10,061
Net cash provided by (used in) financing activities-122,256531-265,582-70,923
Net increase (decrease) in cash, cash equivalents and restricted cash-71,83024,1726,039-39,442
Cash, cash equivalents, and restricted cash, beginning of period287,665238,972209,796302,586
Cash, cash equivalents, and restricted cash, end of period215,835263,144215,835263,144
Reconciliation of cash, cash equivalents, and restricted cash to the unaudited condensed consolidated balance sheets:
Cash and cash equivalents211,553261,342211,553261,342
Restricted cash4,2821,8024,2821,802
Total cash, cash equivalents, and restricted cash215,835263,144215,835263,144

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this press release may be forward-looking statements. Forward-looking statements generally relate to future events or our future financial or operating performance. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” or “will,” or the negative of these words or other similar terms or expressions that concern our expectations, strategy, plans or intentions. Forward-looking statements in this release include, but are not limited to, statements regarding the integration, timing and anticipated benefits and synergies associated with the acquisition of Cylinder Health, statements regarding our expectations regarding our financial position and operating performance, including our outlook and guidance for the fourth quarter of 2026 and guidance for full year 2026 and our assumptions underlying such guidance; our planned leadership transitions; our ability to drive future growth and execute on our goals and strategies; and our expectations regarding our product innovation, including with respect to our Migraine Care Program and the anticipated launch of our integrated Gastrointestinal Care Program in 2027. Our expectations and beliefs regarding these matters may not materialize, and actual results in future periods are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including those more fully described in our filings with the SEC, including in our Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 3, 2026 and in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, when filed with the SEC. The forward-looking statements in this press release are based on information available to us as of the date hereof, and we disclaim any obligations to update any forward-looking statements, except as required by law.³

Earlier releases

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.